RA Treatment Optimisation: Applying Two Decades of Progress

The landscape of rheumatoid arthritis (RA) treatment has undergone a substantial transformation since the early 2000s, driven by a deeper understanding of disease pathophysiology and the introduction of novel therapeutic agents. Prior to this period, RA management often involved a more conservative, step-up approach, frequently resulting in irreversible joint damage and significant functional impairment. The paradigm shift towards early, aggressive intervention with disease-modifying antirheumatic drugs (DMARDs) has been a central theme in rheumatology for the past two decades. This approach aims to suppress inflammation rapidly, prevent structural damage, and preserve physical function.¹

Key to this evolution has been the widespread adoption of treat-to-target (T2T) strategies. T2T involves setting a specific therapeutic goal, typically low disease activity or remission, and adjusting treatment intensity based on regular, objective disease activity assessments. This systematic approach has been shown to improve clinical outcomes compared to standard care. For example, studies have demonstrated that patients managed with T2T protocols achieve remission more frequently and experience less radiographic progression.²

Optimising RA Treatment: A Two-Decade Perspective

The EULAR 2026 discussions on optimising RA treatment drew heavily on the accumulated evidence from numerous clinical trials and real-world registries over the last 20 years. The consensus reinforces that early diagnosis, ideally within 3-6 months of symptom onset, is paramount. This window of opportunity allows for the initiation of effective therapy before significant joint damage occurs.³

Initial therapy typically involves conventional synthetic DMARDs (csDMARDs), with methotrexate remaining the anchor drug. Combination therapy with other csDMARDs, such as sulfasalazine and hydroxychloroquine, is often employed, particularly in patients with higher disease activity or poor prognostic factors. The evidence supports the use of these combinations to achieve disease control more rapidly than monotherapy.⁴

For patients who do not achieve the treatment target within 3-6 months on csDMARDs, escalation to biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) is indicated. The introduction of tumour necrosis factor (TNF) inhibitors in the late 1990s and early 2000s marked a significant milestone, followed by other classes such as IL-6 inhibitors, T-cell costimulation modulators, B-cell depleting agents, and Janus kinase (JAK) inhibitors. These agents have expanded the therapeutic armamentarium considerably.⁵

Comparative effectiveness studies have provided valuable insights into the relative efficacy and safety of these advanced therapies. While direct head-to-head trials between all b/tsDMARDs are limited, network meta-analyses have helped to inform treatment sequencing and selection. For instance, data consistently show that bDMARDs and tsDMARDs are superior to csDMARDs in achieving clinical remission and preventing radiographic progression in patients with an inadequate response to methotrexate.⁶

Safety considerations remain a critical aspect of RA management. While b/tsDMARDs have revolutionised treatment, they are associated with increased risks of infections, and specific agents carry additional safety concerns (e.g., cardiovascular events and venous thromboembolism with some JAK inhibitors). Regular monitoring and careful patient selection are essential to mitigate these risks.⁷

Despite significant progress, challenges persist. A substantial proportion of patients still do not achieve sustained remission, and predicting individual treatment response remains imperfect. Research continues into identifying biomarkers that can guide personalised therapy, moving towards a precision medicine approach in RA. Furthermore, the optimal management of comorbidities, which are prevalent in RA patients, is an ongoing area of focus to improve overall patient outcomes.⁸